Skip to main content

Articles

Page 1 of 14

  1. The aim of the study was to estimate the long-term cost-effectiveness of the Support and Treatment After Replacement (STAR) care pathway for chronic pain after total knee replacement compared with usual postop...

    Authors: Sophie Cole, Sian Noble, Rachael Gooberman-Hill and Rafael Pinedo-Villanueva
    Citation: Cost Effectiveness and Resource Allocation 2024 22:28
  2. The medical pricing system strongly influences physicians’ job satisfaction and patient health outcomes. This study aimed to investigate the current relative value unit (RVU)-based pricing and utility of patie...

    Authors: Yoon Hyo Choi, Tae Hun Kwon, Chin Youb Chung, Naun Jeong and Kyoung Min Lee
    Citation: Cost Effectiveness and Resource Allocation 2024 22:27
  3. Chronic diseases, or non-communicable diseases (NCD), are conditions of long duration and often influenced and contributed by complex interactions of several variables, including genetic, physiological, enviro...

    Authors: George Lin, Kalin Werner, Ada Alqunaiebet, Mariam M. Hamza, Norah Alkanhal, Reem F. Alsukait, Amaal Alruwaily, Severin Rakic, Volkan Cetinkaya, Christopher H. Herbst and Tracy Kuo Lin
    Citation: Cost Effectiveness and Resource Allocation 2024 22:26
  4. The treatment of kidney disease, including hemodialysis, poses challenges in healthcare and finances. Despite limited data on hemodialysis costs and determinants in Ethiopia, existing literature indicates a pa...

    Authors: Tiruneh Amsalu Baye, Hamelmal Gebeyehu, Mahteme Bekele, Semira Abdelmenan, Tigistu Adamu Ashengo and Berhanu Mengistu
    Citation: Cost Effectiveness and Resource Allocation 2024 22:25
  5. There is growing evidence to support the benefits of transcatheter aortic valve implantation (TAVI) over surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis (sSAS) who ...

    Authors: Rob Eerdekens, Suzanne Kats, Janneke PC Grutters, Michelle Green, Judith Shore, Pascal Candolfi, Wija Oortwijn, Pim Van Der Harst and Pim Tonino
    Citation: Cost Effectiveness and Resource Allocation 2024 22:24
  6. Economic evaluations play an important role in the development and implementation of healthcare innovations. For pharmaceutical products, the methodologies used are laid down in guidelines, whereas for medical...

    Authors: C. van Lieshout, G. W. J. Frederix and L. Schoonhoven
    Citation: Cost Effectiveness and Resource Allocation 2024 22:23
  7. Stroke readmissions are considered a marker of health quality and may pose a burden to healthcare systems. However, information on the costs of post-stroke readmissions has not been systematically reviewed.

    Authors: Pedro Abreu, Manuel Correia, Elsa Azevedo, Bernardo Sousa-Pinto and Rui Magalhães
    Citation: Cost Effectiveness and Resource Allocation 2024 22:22
  8. Triple-negative breast cancer (TNBC) is responsible for 10–20% cases of breast cancer and is resulting in rising healthcare costs. Thus, health-economic evaluations are needed to relate clinical outcomes and c...

    Authors: Amelie Wickmann, Melina Sophie Kurte, Julia Jeck, Luisa Camacho, Dennis Klinkhammer, Florian Kron and Robert Dengler
    Citation: Cost Effectiveness and Resource Allocation 2024 22:21
  9. The emergence of high-priced potential cures has sparked significant health policy discussions in South Korea, where the healthcare system is funded through a single-payer National Health Insurance model. We c...

    Authors: Jihyung Hong, Eun-Young Bae, Hye-Jae Lee, Tae-Jin Lee and Philip Clarke
    Citation: Cost Effectiveness and Resource Allocation 2024 22:20
  10. Chronic obstructive pulmonary disease (COPD) is associated with a high readmission rate and poses a significant disease burden. South Korea initiated pilot projects on transitional care services (TCS) to reduc...

    Authors: Yu Seong Hwang, Woo Jin Kim, Tae Hyun Kim, Yukyung Park, Su Mi Jung and Heui Sug Jo
    Citation: Cost Effectiveness and Resource Allocation 2024 22:19
  11. This study aimed to evaluate the cost-effectiveness of a telehealth coaching intervention to prevent gestational diabetes mellitus (GDM) and to calculate the breakeven point of preventing GDM.

    Authors: Susan de Jersey, Syed Afroz Keramat, Angela Chang, Nina Meloncelli, Taylor Guthrie, Elizabeth Eakin and Tracy Comans
    Citation: Cost Effectiveness and Resource Allocation 2024 22:18
  12. The prominent efficacy in terms of increasing progression-free survival (PFS) of Daratumumab, Lenalidomide and dexamethasone (DRd) triplet therapy versus Carfilzomib, Lenalidomide and dexamethasone (KRd) was p...

    Authors: Zahra Goudarzi, Rahil Sadat Shahtaheri, Zhila Najafpour, Haleh Hamedifar and Hamidreza Ebrahimi
    Citation: Cost Effectiveness and Resource Allocation 2024 22:17
  13. The population of older adults continues to grow in Iran, with pharmaceutical costs as a leading driver of household health-related costs. The present study was conducted to estimate the out-of-pocket pharmace...

    Authors: Mehran Faraji, Tahereh Sharifi, Saeed Mohammad-pour, Javad Javan-Noughabi, Ali Aboutorabi, Shaghayegh yousefi and Mihajlo Jakovljevic
    Citation: Cost Effectiveness and Resource Allocation 2024 22:15
  14. The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP...

    Authors: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi and Yazed AlRuthia
    Citation: Cost Effectiveness and Resource Allocation 2024 22:14
  15. Many individuals suffer from normal tension glaucoma (NTG) in China. This study utilized Markov models to evaluate the cost-utility of applying many medications and surgery for mild-stage NTG when disease prog...

    Authors: Di Song and Liwen Wang
    Citation: Cost Effectiveness and Resource Allocation 2024 22:13
  16. There is limited evidence-informed guidance on TISP processes for countries where health technology assessment (HTA) is in a nascent phase. We aimed to explore the range of topic identification, selection and ...

    Authors: Julia Bidonde, Vigdis Lauvrak, Aparna Ananthakrishnan, Pritaporn Kingkaew and Elizabeth F. Peacocke
    Citation: Cost Effectiveness and Resource Allocation 2024 22:12
  17. The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China. The guidelines for hepatitis C recommend the...

    Authors: Yusi Tu, Xiangyan Tang, Dachuang Zhou, Hanqiao Shao, Leyi Liang and Wenxi Tang
    Citation: Cost Effectiveness and Resource Allocation 2024 22:11
  18. Preference elicitation is widely used within health economic evaluations to inform coverage decisions. However, coverage decisions involve questions of social justice and it is unclear what role empirical evid...

    Authors: Wolf Rogowski and Jürgen John
    Citation: Cost Effectiveness and Resource Allocation 2024 22:10
  19. Combined serplulimab and chemotherapy demonstrated improved clinical survival outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) and PD-L1 combined positive scores (CPS) ≥ 1. The pres...

    Authors: Jiahui Li, Chaoqun Xu and Suyun Yuan
    Citation: Cost Effectiveness and Resource Allocation 2024 22:8
  20. Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC). We aimed to assess the cost-effectiv...

    Authors: Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang and Jiyong Wu
    Citation: Cost Effectiveness and Resource Allocation 2024 22:6
  21. Add-on therapy with tiotropium was cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA in a middle-income country.

    Authors: Jefferson Antonio Buendía and Diana Guerrero Patiño
    Citation: Cost Effectiveness and Resource Allocation 2024 22:4
  22. Human communities suffered a vast socioeconomic burden in dealing with the pandemic of coronavirus disease 2019 (COVID-19) globally. Real-word data about these burdens can inform governments about evidence-bas...

    Authors: Majid Nakhaee, Masoud Khandehroo and Reza Esmaeili
    Citation: Cost Effectiveness and Resource Allocation 2024 22:3
  23. Access to convenient quality healthcare at all times is considered a basic human right; however, many countries are still striving to achieve this goal for their populations. The persistent rise in healthcare ...

    Authors: Mohammed Khaled Al-Hanawi and Naseem Al Rahahleh
    Citation: Cost Effectiveness and Resource Allocation 2024 22:2
  24. Maternal and neonatal mortality in low- and middle-income countries is frequently caused by inadequate management of obstetric and neonatal complications and a shortage of skilled health workers. The availabil...

    Authors: Chakib Boukhalfa, Brahim Ouakhzan, Hanane Masbah, Leila Acharai and Saad Zbiri
    Citation: Cost Effectiveness and Resource Allocation 2024 22:1
  25. In China, the healthcare financing structure involves multiple parties, including the government, society and individuals. Medicare Fund is an important way for the Government and society to reduce the burden ...

    Authors: Wenqing Wu, Shujie Long, Arcadio A. Cerda, Leidy Y. Garcia and Mihajlo Jakovljevic
    Citation: Cost Effectiveness and Resource Allocation 2023 21:97
  26. The value of a life is regularly monetised by government departments for informing resource allocation. Guidance documents indicate how economic evaluation should be conducted, often specifying precise values ...

    Authors: Patricia Cubi-Molla, David Mott, Nadine Henderson, Bernarda Zamora, Mendel Grobler and Martina Garau
    Citation: Cost Effectiveness and Resource Allocation 2023 21:96
  27. Psoriasis, an immune-mediated chronic inflammatory disease primarily affecting skin and joints, has varying prevalence rates globally. It manifests in five types, with chronic plaque psoriasis being the most c...

    Authors: Yazed AlRuthia, Almaha H. Alfakhri, Ibtisam Alharbi, Fadi Ali Alghamdi, Miteb A. Alanazi, Abdullah Abdulrahman Alrabiah, Anwar Abdulrazzag Alsouan, Abdulrahman Abdullah Alshaikh and Majed Ali Almasaoud
    Citation: Cost Effectiveness and Resource Allocation 2023 21:95
  28. Although the treatment for end-stage renal disease (ESRD) under Nigeria’s National Health Insurance Authority is haemodialysis (HD), the cost of managing ESRD is understudied in Nigeria. Therefore, this study ...

    Authors: Yakubu Adole Agada-Amade, Daniel Chukwuemeka Ogbuabor, Ejemai Eboreime and Obinna Emmanuel Onwujekwe
    Citation: Cost Effectiveness and Resource Allocation 2023 21:94
  29. According to the Chinese guidelines for lipid management (2023), evolocumab in combination with statins was recommended as secondary prevention of cardiovascular disease. However, because of the variation in t...

    Authors: Yuansheng Wan, Jinyu Liu, Xiaolian Zhan, Yu Zhang and Ruxu You
    Citation: Cost Effectiveness and Resource Allocation 2023 21:93
  30. The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus endocrine therapy (ABE + ET) vs. ET as adjuvant treatment for high-risk hormone receptor-positive and human epidermal growth fa...

    Authors: Qiran Wei, YuTing Xu, Wei Liu and Xin Guan
    Citation: Cost Effectiveness and Resource Allocation 2023 21:91
  31. This study investigates Iranian men’s willingness to pay (WTP) for prostate cancer (PCa) screening and influencing factor, along with the impact of information.

    Authors: Hiro Farabi, Najmeh Moradi, Aziz Ahmadzadeh, Seyed Mohammad Kazem Agamir, Abdolreza Mohammadi and Aziz Rezapour
    Citation: Cost Effectiveness and Resource Allocation 2023 21:89
  32. To investigate the cost-effectiveness of using Implant Movement Analysis (IMA) to follow up suspected aseptic loosening when the diagnosis after an initial X-ray is not conclusive, compared with a diagnostic p...

    Authors: Davide Lovera, Olof Sandberg, Maziar Mohaddes and Hanna Gyllensten
    Citation: Cost Effectiveness and Resource Allocation 2023 21:88
  33. Demonstrating safety and efficacy of new medical treatments requires clinical trials but clinical trials are costly and may not provide value proportionate to their costs. As most health systems have limited r...

    Authors: Piers Gillett, Robert K Mahar, Nancy R Tran, Mark Rosenthal and Maarten IJzerman
    Citation: Cost Effectiveness and Resource Allocation 2023 21:87
  34. Breast cancer represents the most prevalent cancer among Swedish women. Although considerable research has investigated the cost-effectiveness of emerging innovative medical treatments for breast cancer, studi...

    Authors: Phu Duy Pham, Muchandifunga Trust Muchadeyi and Lars Lindholm
    Citation: Cost Effectiveness and Resource Allocation 2023 21:86
  35. Management of COVID-19 patients with mild and moderate symptoms could be isolated at home isolation (HI), community isolation (CI) or hospitel. However, it was still unclear which strategy was more cost-effect...

    Authors: Unyaporn Suthutvoravut, Patratorn Kunakorntham, Anchisatha Semayai, Amarit Tansawet, Oraluck Pattanaprateep, Pongsathorn Piebpien, Pawin Numthavaj, Ammarin Thakkinstian and Pongsakorn Atiksawedparit
    Citation: Cost Effectiveness and Resource Allocation 2023 21:85
  36. Prostate cancer is the second most common cancer in males worldwide and the third most common among Iran’s male population. However, there is a lack of evidence regarding its direct and indirect costs in low a...

    Authors: Farbod Alinezhad, Farhad Khalili, Hossein Zare, Chunling Lu, Zahra Mahmoudi and Mahmood Yousefi
    Citation: Cost Effectiveness and Resource Allocation 2023 21:84
  37. Artificial Intelligence (AI) represents a significant advancement in technology, and it is crucial for policymakers to incorporate AI thinking into policies and to fully explore, analyze and utilize massive da...

    Authors: Maryam Ramezani, Amirhossein Takian, Ahad Bakhtiari, Hamid R. Rabiee, Ali Akbar Fazaeli and Saharnaz Sazgarnejad
    Citation: Cost Effectiveness and Resource Allocation 2023 21:83
  38. In recent years, numerous guidelines and expert consensus have recommended the inclusion of digital technologies and products in cardiac rehabilitation. Digital therapeutics (DTx) is an evidence-based medicine...

    Authors: Tianyi Liu, Yiyang Zhan, Silei Chen, Wenhong Zhang and Jian Jia
    Citation: Cost Effectiveness and Resource Allocation 2023 21:82

    The Correction to this article has been published in Cost Effectiveness and Resource Allocation 2024 22:16

  39. Chronic Kidney Disease (CKD) patients often require long-term care, and while Hemodialysis (HD) is the standard treatment, Comprehensive Conservative Care (CCC) is gaining popularity as an alternative. Economi...

    Authors: Telma Zahirian Moghadam, Jane Powell, Afshan Sharghi and Hamed Zandian
    Citation: Cost Effectiveness and Resource Allocation 2023 21:81
  40. Monetizing health has sparked controversy and has implications for pricing strategies of emerging health technologies. Medical insurance payers typically set up thresholds for quality-adjusted life years (QALY...

    Authors: Qian Peng, Yue Yin, Min Liang, Mingye Zhao, Taihang Shao, Yaqian Tang, Zhiqing Mei, Hao Li and Wenxi Tang
    Citation: Cost Effectiveness and Resource Allocation 2023 21:80
  41. In recent years, international academics recognized that quality-adjusted life-years (QALYs) may not always fully capture the benefits produced by an intervention, and considered incorporating additional eleme...

    Authors: Lihua Sun, Shiqi Li and Xiaochen Peng
    Citation: Cost Effectiveness and Resource Allocation 2023 21:79
  42. Dealing with randomness is a crucial aspect that cost-effectiveness analysis (CEA) tools need to address, but existing stochastic CEA tools have rarely examined risk and return from the perspective of populati...

    Authors: Ermo Chen
    Citation: Cost Effectiveness and Resource Allocation 2023 21:78
  43. Hip fractures are a common and costly health problem, resulting in significant morbidity and mortality, as well as high costs for healthcare systems, especially for the elderly. Implementing surgical preventiv...

    Authors: Momin S. Alnemer, Konstantin E. Kotliar, Valentin Neuhaus, Hans-Christoph Pape and Bernhard D. Ciritsis
    Citation: Cost Effectiveness and Resource Allocation 2023 21:77
  44. The increasing global prevalence of atrial fibrillation (AF) has led to a growing demand for stroke prevention strategies, resulting in higher healthcare costs. High-quality economic evaluations of stroke prev...

    Authors: Sumudu A. Hewage, Rini Noviyani, David Brain, Pakhi Sharma, William Parsonage, Steven M. McPhail, Adrian Barnett and Sanjeewa Kularatna
    Citation: Cost Effectiveness and Resource Allocation 2023 21:76

Annual Journal Metrics

  • 2022 Citation Impact
    2.3 - 2-year Impact Factor
    2.4 - 5-year Impact Factor
    0.916 - SNIP (Source Normalized Impact per Paper)
    0.530 - SJR (SCImago Journal Rank)

    2023 Speed
    6 days submission to first editorial decision for all manuscripts (Median)
    157 days submission to accept (Median)

    2023 Usage 
    595,859 downloads
    2,584 Altmetric mentions